Quetiapine, QTc interval prolongation, and torsade de pointes: A review of case reports

Therapeutic Advances in Psychopharmacology

Volumn 4, Issue 3, 2014, Pages 130-138

  Hasnain, Mehrul ^a   Vieweg, W Victor R ^b   Howland, Robert H ^b   Kogut, Christopher ^c   Breden Crouse, Ericka L ^c   Koneru, Jayanthi N ^c   Hancox, Jules C ^c   Digby, Geneviève C ^d   Baranchuk, Adrian ^d   Deshmukh, Anand ^e   Pandurangi, Ananda K ^f  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d QUEEN S UNIVERSITY   (Canada)

^e CREIGHTON UNIVERSITY CARDIAC CENTER   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

case reports; drug induced QTc interval prolongation; quetiapine; risk factors; torsade de pointes

Indexed keywords

EID: 84998090344     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125313510194     Document Type: Review

References (38)

1. Aghaienia N. Brahm N. Lussier K. Washington N. (2011) Probable quetiapine-mediated prolongation of the QT interval. J Pharm Pract 24: 506–512.
2. Anonymous (2011) Quetiapine (Seroquel) and QT-interval prolongation. Med Lett Drugs Ther 53: 79–80.
3. Anonymous (2013) Astrazeneca Quetiapine (Seroquel) Prescribing Information 2013. Available at: http://www1.astrazeneca-us.com/pi/seroquel.pdf
4. Baranchuk A. Simpson C. Methot M. Gibson K. Strum D. (2008) Corrected QT interval prolongation after an overdose of escitalopram, morphine, oxycodone, zopiclone and benzodiazepines. Can J Cardiol 24: e38-e40.
5. Beach S. Celano C. Noseworthy P. Januzzi J. Huffman J. (2013) QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics 54: 1–13.
6. Bednar M. Harrigan E. Anziano R. Camm A. Ruskin J. (2001) The QT interval. Prog Cardiovasc Dis 43(5 Suppl. 1): 1–45.
7. Beelen A. Yeo K. Lewis L. (2001) Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. Hum Exp Toxicol 20: 215–219.
8. Benoit S. Mendelsohn A. Nourjah P. Staffa J. Graham D. (2005) Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Examination Survey. Eur J Cardiovasc Prev Rehabil 12: 363–368.
9. Bodmer M. Burkard T. Kummer O. Beyrau R. Krahenbuhl S. Haschke M. (2008) Pharmacokinetics and pharmacodynamics of quetiapine in a patient with a massive overdose. Ther Drug Monit 30: 553–556.
10. Darpo B. (2010) The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance. Br J Pharmacol 159: 49–57.
11. Devlin J. Roberts R. Fong J. Skrobik Y. Riker R. Hill N. et al. (2010) Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Crit Care Med 38: 419–427.
12. Digby G. Machaalany J. Malik P. Methot M. Simpson C. Redfearn D. et al. (2010) Multifactorial QT interval prolongation. Cardiol J 17: 184–188.
13. Digby G. Perez Riera A. Barbosa Barros R. Simpson C. Redfearn D. Methot M. et al. (2011) Acquired long QT interval: a case series of multifactorial QT prolongation. Clin Cardiol 34: 577–582.
14. Franz M. (2008) Bazett, Fridericia, or Malik? Heart Rhythm 5: 1432–1433.
15. Furst B. Champion K. Pierre J. Wirshing D. Wirshing W. (2002) Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin. Biol Psychiatry 51: 264–265.
16. Gajwani P. Pozuelo L. Tesar G. (2000) QT Interval prolongation associated with quetiapine (Seroquel) overdose. Psychosomatics 41: 63–65.
17. Geller W. Smith M. Winter H. Brecher M. (2002) In response to Furst et al, “Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin”. Biol Psychiatry 52: 914.
18. Gupta S. Nienhaus K. Shah S.A. (2003) Quetiapine and QTc Issues: A Case Report. J Clin Psychiatry 64: 612–613.
19. Hancox J. McPate M. El Harchi A. Zhang Y. (2008) The Herg potassium channel and Herg screening for drug-induced torsades de pointes. Pharmacol Ther 119: 118–132.
20. Hasnain M. Vieweg WV. Howland R. Kogut C. Crouse E. Koneru J. et al. (2013) Guest editorial. Quetiapine and the need for a thorough QT/QTc study. J Clin Psychopharmacol (accepted). DOI: 10.1097/JCP.0000000000000075.
21. Hustey F. (1999) Acute quetiapine poisoning. J Emerg Med 17: 995–997.
22. Indik J. Pearson E. Fried K. Woosley R. (2006) Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. Heart Rhythm 3: 1003–1007.
23. Kannankeril P. Norris K. Carter S. Roden D. (2011) Factors affecting the degree of QT prolongation with drug challenge in a large cohort of normal volunteers. Heart Rhythm 8: 1530–1534.
24. Kongsamut S. Kang J. Chen X. Roehr J. Rampe D. (2002) A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol 450: 37–41.
25. Kurth J. Maguire G. (2004) Pediatric case report of quetiapine overdose and QTc prolongation. Ann Clin Psychiatry 16: 229–231.
26. Ng T. Olsen K. McCartan M. Puumala S. Speidel K. Miller M. et al. (2010) Drug-induced QTc-interval prolongation in the intensive care unit: incidence and predictors. J Pharm Pract 23: 19–24.
27. Pierre J. Wirshing D. Wirshing W. (2002) Reply. Biol Psychiatry 52: 914–915.
28. Psychopharmacological Drugs Advisory Committee (2000) Briefing document for Zeldox® capsules (Ziprasidone Hcl) Pfizer. www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1a.pdf (accessed 7 January 2012).
29. Reinsch N. Buhr C. Krings P. Kaelsch H. Neuhaus K. Wieneke H. et al. (2009) Prevalence and risk factors of prolonged QTc interval in HIV-infected patients: results of the HIV-Heart Study. HIV Clin Trials 10: 261–268.
30. Strachan P. Benoff B. (2006) Mental status change, myoclonus, electrocardiographic changes, and acute respiratory distress syndrome induced by quetiapine overdose. Pharmacotherapy 26: 578–582.
31. Tisdale J. Jaynes H. Kingery J. Mourad N. Trujillo T. Overholser B. et al. (2013) Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 6: 479–487.
32. Vieweg WV. Hasnain M. Howland R. Clausen T. Koneru J. Kogut C. et al. (2013) Methadone, QTc interval prolongation, and torsade de pointes. case reports offer clinicians the best guidance for this problem. Ther Adv Psychopharmacol 21 January (Epub ahead of print). DOI: 10.1177/2045125312469982
33. Vieweg WV. Hasnain M. Howland R. Hettema J. Kogut C. Wood M. et al. (2012) Citalopram, QTc interval prolongation, and torsade de pointes. how should we apply the recent FDA ruling? Am J Med 125: 859–868.
34. Vieweg WV. Hasnain M. Wood M. Fernandez A. Lesnefsky E. Pandurangi A. (2011) cardiometabolic risks of antidepressant and antipsychotic drugs, part 1. Proarrhythmic risks of antidepressant and antipsychotic drugs. Psychiatr Times 28: 50–55.
35. Vieweg WV. Schneider R. Wood M. (2005) Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine. Acta Psychiatr Scand 112: 319–323.
36. Vieweg WV. Wood M. Fernandez A. Beatty-Brooks M. Hasnain M. Pandurangi A. (2009) Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging 26: 997–1012.
37. Vincent G. (1999) Long QT syndrome. Cardiol Clin 18: 309–325.
38. Viskin S. Justo D. Halkin A. Zeltser D. (2003) Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis 45: 415–427.